



H.R. 6130, *Alzheimer's Screening and Prevention (ASAP) Act*

Rep. Buchanan (R-FL)

Background:

- Over **7 million Americans** aged 65+ are currently diagnosed with Alzheimer's disease. That number is expected to grow to **13 million by 2050**.
- Annual health care cost of Alzheimer's disease in **2026 is projected to be \$263 billion**, with over **\$222 billion** of such cost attributed to late-stage institutionalized care and hospice care.
- **60% of rural Americans live in areas without access to specialists** like neurologists and memory care specialists, forcing patients to **travel long distances** for necessary imaging tests and lumbar punctures, delaying a patient's potential diagnosis.
- Once Alzheimer's disease causes neurodegeneration, clinical damage **is irreversible**.
- Fortunately, new blood-based screening tests for Alzheimer's disease are now available to patients and can **diagnose Alzheimer's disease before Mild Cognitive Impairment** occurs.
 - Innovative blood-based biomarker tests can detect pre-clinical Alzheimer's disease with **90% accuracy** through a blood draw in a primary care setting.
 - Additionally, new and innovative treatments in late-stage clinical trials are showing promise to **slow or stop progression** of Alzheimer's disease.
- Early detection and timely intervention is estimated to save nearly **\$14,300 per person annually** by mitigating acute crises and delaying nursing facility admissions.
- Currently, statutory gaps leave Medicare **without a coverage pathway for these early-detection screening tests**, blocking patient access to timely, life-altering care.

H.R. 6130, *Alzheimer's Screening and Prevention (ASAP) Act*:

- Provides **transitional Medicare coverage** and reimbursement for FDA-approved blood-based Alzheimer's disease screening tests for beneficiaries most impacted by early screening.
 - Newly eligible Medicare beneficiaries, and those becoming eligible within the next few years, will receive **access to covered Alzheimer's screening tests**, with those individuals continuing to receive coverage in perpetuity.
 - Traditional coverage decisions can further expand coverage to all Medicare beneficiaries.
- Requires the cognitive impairment test in the Medicare Annual Wellness Visit to be performed using a **cognitive impairment detection tool identified by the National Institute on Aging**.

Endorsed By: Alzheimer's Association; Alzheimer's Impact Movement (AIM); UsAgainstAlzheimer's; Alliance for Aging Research; Americans for Tax Reform (ATR)